Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

uniQure Terug naar discussie overzicht

Wat is de waarde van uniQure?

7.806 Posts
Pagina: «« 1 ... 224 225 226 227 228 ... 391 »» | Laatste | Omlaag ↓
  3. QLVT 23 mei 2016 22:12

    • QLVT

      Lid sinds: 13 sep 2011

      Laatste bezoek: 03 apr 2024

    • Aanbevelingen

      Ontvangen: 48

      Gegeven: 3

    •    Aantal posts: 531

    Ikke niet meer,zit er nog een beetje in ,veel winst +40 % verdamd bij mij van afgelopen jaar,maar als je heen gaat wil ik graag jouw verslag mening lezen PROF DOLLAR groetjes
  4. forum rang 10 rationeel 23 mei 2016 23:23

    • rationeel

      Lid sinds: 07 okt 2004

      Laatste bezoek: 19 apr 2024

    • Aanbevelingen

      Ontvangen: 22854

      Gegeven: 1806

    •    Aantal posts: 65.808

    Met een lager dan gemiddeld volume een klein plusje. 12,68 wacht geduldig, samen met naar beneden gezakte 12,8117.
  5. [verwijderd] 23 mei 2016 23:38

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Prof. Dollar schreef op 23 mei 2016 21:02:

    Wie van jullie komt er woensdag 15 juni naar de AVA?
    Hoe laat (kan ik natuurlijk ook zelf opzoeken...)? Ben bang dat Lynx nog uitnodigingen naar mijn oude adres stuurt.
  11. Prof. Dollar 25 mei 2016 19:32

    • Prof. Dollar

      Lid sinds: 04 mrt 2011

      Laatste bezoek: 19 apr 2024

    • Aanbevelingen

      Ontvangen: 192

      Gegeven: 52

    •    Aantal posts: 2.283

    quote:

    Dogder schreef op 25 mei 2016 10:19:

    Wat vinden jullie van de nieuwe ceo?
    cc.talkpoint.com/ubsx001/052316a_ae/?...
    Aanstekelijk enthousiasme spat er niet van af. Inhoudelijk heb ik niks nieuws gehoord. Toegegeven, de delivery was iets beter dan de voorgaande keer. Hopelijk hanteert hij het adagium 'intern beginnen, is extern winnen'.

    Wat is jouw indruk?
  14. forum rang 10 rationeel 25 mei 2016 23:26

    • rationeel

      Lid sinds: 07 okt 2004

      Laatste bezoek: 19 apr 2024

    • Aanbevelingen

      Ontvangen: 22854

      Gegeven: 1806

    •    Aantal posts: 65.808

    Met gemiddeld volume een positieve candle. Slot 12,62. Het schiet op;)
    Wachten op 12,68...12,7475...13,97...14,3908.
    Positief punt is, vanaf 17-03-16...10,61...Hogere bodems.
  15. forum rang 10 rationeel 26 mei 2016 22:57

    • rationeel

      Lid sinds: 07 okt 2004

      Laatste bezoek: 19 apr 2024

    • Aanbevelingen

      Ontvangen: 22854

      Gegeven: 1806

    •    Aantal posts: 65.808

    Vandaag met lager dan gemiddeld volume een negatieve candle. Het aandeel ondervond op korte termijn weerstand op 12,89...(12,90), en ging met een gap down.
    Weerstanden...12,68....12,7377. Steun...12,16...11,85...11,65.
  16. forum rang 10 rationeel 27 mei 2016 23:02

    • rationeel

      Lid sinds: 07 okt 2004

      Laatste bezoek: 19 apr 2024

    • Aanbevelingen

      Ontvangen: 22854

      Gegeven: 1806

    •    Aantal posts: 65.808

    DAG grafiek: Bij redelijk volume een rode candle. 11.85 bood steun. Het is te hopen dat 11,70 houdt. Naar boven is de belangrijke weerstand inmiddels 12,7179.

    WEEK grafiek: High...12,89; Low...11,81. Candle is een doji.
  17. Prof. Dollar 28 mei 2016 09:28

    • Prof. Dollar

      Lid sinds: 04 mrt 2011

      Laatste bezoek: 19 apr 2024

    • Aanbevelingen

      Ontvangen: 192

      Gegeven: 52

    •    Aantal posts: 2.283

    Wat kunnen we binnenkort verwachten: publicatie Q1, presentatie Hem. B cohort 1 en AVA.

    En mogelijk gaat de uitspraak van de FDA, die deze week tot nadere orde is uitgesteld, over toekenning New Drug Application (NDA)voor eteplirsen van Sarepta voor marktbeweging zorgen.

    Oh ja, en komende maandag is de Nasdaq in verband met Memorial Day gesloten.

    Goed weekend!
  18. [verwijderd] 31 mei 2016 13:16

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Uniqure Q1
    uniQure Announces Results for First Quarter 2016
    Tue May 31, 2016 5:00 AM|GlobeNewswire
    AMSTERDAM, the Netherlands, May 31, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE) (NASDAQ (NBI): QURE), a leader in human gene therapy, today announced financial results for the first quarter ending March 31, 2016, and provided a corporate update.

    "We are very pleased with our progress so far in 2016 as we continue to advance our clinical and preclinical programs and build out our gene therapy platform," commented Daniel Soland, Chief Executive Officer of uniQure. "We achieved two important milestones related to our hemophilia B gene therapy AMT-060: announcing our first clinical data from the study's low-dose cohort and completing the dosing of all 10 patients in the study, including the high-dose cohort. Additionally, we presented and published data from several preclinical studies, including proof-of-concept data for AMT-130 in Huntington's disease and several new technologies designed to optimize gene therapy and expand its applicability to patients across the world. We look forward to presenting additional data on AMT-060 at EHA in June and remain on track to present new data from our high-dose cohort before the end of the year."

    Corporate Highlights

    Pipeline and Technology Updates

    Liver/Metabolic Diseases

    Announced Upcoming Oral Presentation of Clinical Data from AMT-060 Low-Dose Cohort at EHA – On May 19, 2016 the Company announced that additional data from its Phase I/II trial of AMT-060 in hemophilia B will be presented on June 11, 2016 at the 21st Congress (CACOX) of the European Hematology Association ("EHA") in Copenhagen, Denmark. The oral presentation by the clinical investigator will include new and updated data on five patients enrolled in the study's low-dose cohort. uniQure will also host a webcast conference call to discuss the results at 02.00 pm CET/ 8:00 am EDT on Monday, June 13, 2016.

    Completed Dosing of AMT-060 Phase I/II Clinical Trial – The Company announced today that it has successfully treated all five patients in its high-dose cohort, thus completing the enrollment of its 10 patient, Phase I/II study of AMT-060. AAV5 continues to exhibit a very low screening failure rate, with all patients screened in the study testing negative for pre-existing, anti-AAV5 antibodies. The Company anticipates presenting data on the high-dose cohort before the end of the year.

    Published Phase I Clinical Data from AAV5-Based Gene Therapy in AIP – On May 17, 2016, results from the AIPGENE Consortium-led Phase I clinical trial using uniQure's AAV5-based gene therapy to treat acute intermittent porphyria (AIP) were published online in the Journal of Hepatology. In the trial, a total of eight patients in four dose cohorts received a single intravenous injection of uniQure's AAV5 vector-PBGD transgene gene therapy in doses ranging from 2x1012 gc/kg to 1.8x1013 gc/kg, without the use of prophylactic steroid therapy. The therapy was well-tolerated in all patients, with no cellular immune responses to either the vector or the transgene, and no transaminase elevations or serious adverse events related to the gene therapy. Including these patients, a total of 27 patients have been screened for pre-existing anti-AAV5 antibodies in three clinical programs to date, with only one AIP patient testing marginally positive for pre-existing antibodies. While the Company currently does not have plans to conduct further studies for AIP, these data support the broad safety and applicability of AAV5 as a differentiated vector serotype due to the low prevalence of pre-existing anti-AAV5 antibodies.
    CNS Diseases

    Initiated Extension Protocol for Phase I/II Study of AMT-110 in Sanfilippo B – On April 4, 2016, the Company announced that it has assumed the sponsorship of the Phase I/II extension study from the academic consortium comprised of Institut Pasteur, the French Muscular Dystrophy Association, Vaincre les Maladies Lysosomales and Institut National de la Santé et de la Recherche Médicale (INSERM). The Company has initiated the 30-month follow-up of the four patients treated in the study and anticipates presenting additional data in early 2017.
    Technology Programs

    Presented Data from Multiple Preclinical Studies of New Gene Therapy Technologies at ASGCT – On May 9, 2016, the Company announced data from several preclinical research programs focused on the development and validation of optimized gene therapy delivery systems, AAV re-administration, regulated gene expression and total brain transduction. The results were presented in poster sessions at the American Society of Gene and Cell Therapy (ASGCT) 19th Annual Meeting in Washington D.C. and highlight the progress uniQure has made in developing new technologies designed to improve gene therapy and broaden its applicability to patients.
  19. [verwijderd] 31 mei 2016 13:17

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Human Resource and Organizational Updates

    Added Key Talent – On May 3, 2016, the Company announced the appointment of Paul Firuta as Chief Commercial Officer. Mr. Firuta, who held similar positions at NPS Pharmaceuticals (NPSP) and ViroPharma, will oversee global commercial and portfolio planning and program management, as well as will work closely with the Company's cross-functional teams in building relationships with patient advocacy groups and key opinion leaders.

    Entered Lease for New Amsterdam Facility – On March 1, 2016, the Company entered into a lease contract for a new 9,200 square meter facility in Amsterdam designed to meet the needs of its fully-integrated gene therapy operations and expanding product pipeline. The Company has commenced the refurbishment of the space and intends to initiate the consolidation of its current three Amsterdam sites into the new facility by the end of the year.

    Proposed Corporate Governance Changes – On May 9, 2016, the Company announced the nomination of Jack Kaye to the Board of Directors. Mr. Kaye, a seasoned financial executive with over 40 years of diversified experience, will also chair the Company's Audit Committee. Additionally, the Company announced its intention to transition from the current two-tier Supervisory Board and Management Board structure to a single Board of Directors with executive and non-executive members. As part of the governance transition, Ferdinand Verdonck and Joseph Fezcko plan to retire from the Supervisory Board and Mr. Soland and Matthew Kapusta, Chief Financial Officer, will stand for election to the single Board as executive directors.
    Corporate Finance and Other Updates

    Lowered Cost and Expanded Flexibility of Venture Debt Agreement – On May 6, 2016, the Company executed a second amended and restated loan agreement with Hercules Technology Growth Capital, Inc. (Hercules). The loan agreement includes a total commitment from Hercules of up to $40 million, of which $20 million is currently outstanding. The Company has not drawn down any additional loan amounts. The interest rate will be reduced from 10.25% to 8.25% per annum with a backend fee of 4.85% and facility fee of 0.75% of the outstanding loan amounts. The interest-only payment period is initially set at 18 months from May 6, 2016, but can be extended to 36 months under certain conditions. The maturity date of the loan facility was also extended from June 30, 2017 to March 1, 2020.

    Established Stock Purchase Plan for Chief Executive Officer – On April 18, 2016, Mr. Soland established a pre-arranged personal stock purchase plan to acquire up to 100,000 ordinary shares of the Company's stock. The plan is intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transactions under this purchasing plan will commence no earlier than June 13, 2016.
    Financial Highlights

    As of March 31, 2016, the Company held cash and cash equivalents of €184.6 million, compared with of €203.5 million, as of December 31, 2015, a decrease of €18.9 million. The decrease includes €16.0 million of cash used in operating, investing and financing activities during the three months ended March 31, 2016, in addition to a €2.9 million loss related to foreign currency effects on U.S. dollar-denominated deposits.

    Licensing and collaboration revenues for the three months ended March 31, 2016 were €3.9 million, compared with €1.1 million for the comparable period in 2015. The change was primarily due to the amortization of upfront payments and target designation fees received from BMS in the second and third quarters of 2015, and the increase of research activities associated with S100A1 for heart failure, which are fully reimbursed by BMS in accordance with our collaboration agreement.

    Research and development expenses were €15.1 million for the three months ended March 31, 2016, compared with €10.1 million for the comparable period in 2015. The increase is mainly due to the initiation of our Phase I/II clinical study of AMT-060 in hemophilia B, an increase in activities in support of our collaboration agreement with BMS, which closed in May 2015, and the continued progression of our various research programs, including our collaboration with 4D and preclinical product candidates for hemophilia A and Huntington's disease.

    Selling, general and administrative expenses were €6.6 million for the three months ended March 31, 2016, compared with €4.2 million for the comparable period in 2015. The change primarily related to increases in the numbers of employees, contractors and consultants, as well as increases in professional fees and expenses associated with the Glybera global registry and Phase IV study, which are currently classified as selling, general and administrative expenses, but were previously capitalized in the same period in 2015, prior to the commencement of Glybera commercialization.
  20. [verwijderd] 31 mei 2016 13:17

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    The net loss for the first quarter 2016 was €20.6 million, or €0.83 per share, compared with €12.6 million, or €0.69 per share, for the first three months of 2015.

    About uniQure

    uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniQure.com

    uniQure Forward-Looking Statements

    This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the development of our gene therapy product candidates, the success of our collaborations and the risk of cessation, delay or lack of success of any of our ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with collaboration arrangements, our and our collaborators' clinical development activities, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure's 2015 Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 4, 2016. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

    UNIQURE N.V.
    Unaudited Condensed Consolidated Balance Sheet
    (€ in thousands)

    December 31, March 31,
    2015 2016
    Assets
    Non-current assets
    Goodwill 442 442
    Intangible assets other than Goodwill 7,209 7,030
    Property, plant and equipment 23,820 23,602
    Other non-current assets 1,142 1,650
    Total non-current assets 32,613 32,724
    Current assets
    Receivables from related parties 3,792 1,504
    Trade and other receivables 1,730 3,606
    Inventories 435 407
    Cash and cash equivalents 203,532 184,643
    Total current assets 209,489 190,160
    Total assets 242,102 222,884
    Equity
    Share capital 1,216 1,241
    Share premium 344,803 345,530
    Other reserves 26,026 27,633
    Accumulated deficit (252,561) (273,137)
    Total equity 119,484 101,267
    Liabilities
    Non-current liabilities
    Borrowings 13,434 11,860
    Derivative financial instruments - related party 530 351
    Deferred rent 5,737 5,484
    Deferred revenue 75,852 74,665
    Contingent consideration 2,687 2,741
    Total non-current liabilities 98,240 95,101
    Current liabilities
    Trade and other payables 11,220 11,865
    Derivative financial instruments - related parties 992 541
    Borrowings 5,124 5,986
    Borrowings – derivative 238 132
    Deferred rent 579 567
    Deferred revenue 6,225 6,098
    Provisions -- 1,327
    Total current liabilities 24,378 26,516
    Total liabilities 122,618 121,617
7.806 Posts
Pagina: «« 1 ... 224 225 226 227 228 ... 391 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.840
AB InBev 2 5.282
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.579 46.092
ABO-Group 1 18
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 253
Accsys Technologies 22 8.871
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 160
ADMA Biologics 1 31
Adomos 1 126
AdUX 2 457
Adyen 13 16.146
Aedifica 2 828
Aegon 3.257 320.010
AFC Ajax 537 7.010
Affimed NV 2 5.736
ageas 5.843 109.775
Agfa-Gevaert 13 1.854
Ahold 3.536 73.977
Air France - KLM 1.024 34.302
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.682
Alfen 12 16.002
Allfunds Group 3 1.122
Almunda Professionals (vh Novisource) 651 4.246
Alpha Pro Tech 1 17
Alphabet Inc. 1 324
Altice 106 51.196
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.484 114.756
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.819 240.164
AMG 965 125.588
AMS 3 73
Amsterdam Commodities 303 6.512
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 382
Antonov 22.632 153.605
Aperam 91 14.105
Apollo Alternative Assets 1 17
Apple 5 313
Arcadis 251 8.613
Arcelor Mittal 2.023 318.576
Archos 1 1
Arcona Property Fund 1 266
arGEN-X 15 9.094
Aroundtown SA 1 175
Arrowhead Research 5 9.249
Ascencio 1 20
ASIT biotech 2 697
ASMI 4.107 37.534
ASML 1.762 76.481
ASR Nederland 18 4.117
ATAI Life Sciences 1 7
Atenor Group 1 322
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 29 10.626
Axsome Therapeutics 1 177
Azelis Group 1 49
Azerion 7 2.657

Macro & Bedrijfsagenda

  1. 22 april

    1. NL investeringen februari
    2. SAP Q1-cijfers
    3. NL consumentenvertrouwen april
    4. NL prijzen bestaande koopwoningen maart
    5. ING jaarvergadering
    6. VS Chicago Fed-index maart
    7. EU consumentenvertrouwen april (voorlopig)

  2. 23 april

    1. Japan samengestelde inkoopmanagersindex april
    2. Novartis Q1-cijfers
    3. Renault Q1-cijfers
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda